BioCentury
ARTICLE | Clinical News

CHMP backs approval of BioCryst's Alpivab

March 1, 2018 10:43 PM UTC

EMA's CHMP recommended approval of Alpivab peramivir from BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to treat uncomplicated influenza. The injectable formulation of viral neuraminidase inhibitor is ...

BCIQ Company Profiles

BioCryst Pharmaceuticals Inc.

BCIQ Target Profiles

Influenza virus neuraminidase